Together 3.7.3
Delos Sheppard
Rebuilding Together is committed to diversity, equity and inclusion (DE&I) as an organizational imperative. We believe that to achieve our goals, we must embrace a broad vision of success that builds on multiple perspectives as the means through which to learn, innovate and grow. We know that we will be most effective by creating a culture that values and leverages differences as an organizational strength as we partner with, and serve, diverse communities and residents. Our work affirms human dignity through our commitment to safe and healthy housing for all.
In 1973, a small group of people in Midland, Texas, realized a growing need in their community. Homes in their community had fallen into disrepair and their neighbors could not afford to fix them on their own. The group volunteered their time and skills to rehabilitate the homes of their neighbors. Realizing the potential impact of this work, the group formed Christmas in April, with the intent of performing repair and rehabilitation work in their community every April.
Today, Rebuilding Together has grown into a leading national nonprofit organization repairing the homes of people in need and revitalizing our communities. Through our network of affiliates, we work proactively and collaboratively with community leaders, long-term residents, funders and volunteers to foster dialogue and create safe, healthy communities together across the country.
The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers
The Together for CHANGE initiative seeks to address inequities in STEM careers and research with a two-pronged approach. First, the Diaspora Human Genomics Institute (DHGI) will establish a grant program to support research and educational capacity in genomics and related fields at Meharry Medical College, as well as broader STEM programs in racially diverse communities for grade school-aged children. Second, in close consultation with the local Black community through listening sessions and ongoing input, the DHGI will help facilitate the building of the largest African ancestry genomics research database, composed of de-identified genomic and phenotypic data from up to 500,000 volunteer participants.
Meharry Medical College, one of the oldest and largest historically Black academic health sciences centers in the U.S., is a co-founder and academic convener of this initiative. The DHGI, a newly chartered non-profit organization, will serve as the governing organization for Together for CHANGE. Data collected from the Together for CHANGE initiative will be secured and managed by the DHGI to ensure the integrity and transparency of all activities of the initiative.
Additionally, the DHGI will form an ethics committee with leaders from the Black community to provide stewardship of the data. Accenture will also provide support as a strategic partner to the DHGI as the program rolls out.
Meharry worked with Regeneron Genetics Center to convene three founding partners for the initiative, AstraZeneca, Novo Nordisk, and Roche, and welcome participation from additional partners. Each organization intends to make contributions worth $20 million during the initiative, with Regeneron Genetics Center also undertaking and funding the sequencing of genetic samples. The DHGI launch is underway, with more information about study participation and grants to be available later this year.
Second, in close consultation with the local Black community through listening sessions and ongoing input, the DHGI will help facilitate the building of the largest African ancestry genomics research database, composed of de-identified genomic and phenotypic data from up to 500,000 volunteer participants. People of African ancestry represent the most genetically diverse population in the world, and there is a massive underrepresentation of this group in available genomic data. The focus on increasing information around African ancestry strives to improve health outcomes for this community through deeper understanding of their genetics.
Today, Meharry includes schools of medicine, dentistry, graduate studies and applied computational sciences and is home to The Institute for Global Public Health and Center for Health Policy. Degrees include Doctor of Medicine (M.D.), Doctor of Dental Surgery (D.D.S.), Master of Public Health (M.P.H.), Master of Health Science (M.H.S.), and Doctor of Philosophy (Ph.D.).
In addition to providing quality professional health care education, exemplary patient care, and compassionate community outreach, Meharry Medical College produces the Journal of Health Care for the Poor and Underserved, a public health journal.
About the Regeneron Genetics Center
The Regeneron Genetics Center LLC (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications. RGC is tackling large-scale sequencing and analytical approaches and has established numerous collaborations with leading human genetics researchers. To enable this large-scale sequencing and analysis program, RGC utilizes fully automated sample preparation and data processing, as well as cutting-edge cloud-based informatics.
At RGC, scientists around the globe with diverse skills and backgrounds work together to uncover the genetic basis of human disease. Their efforts have culminated in landmark discoveries like CIDEB in NASH and have led to multiple new therapeutic development programs at Regeneron across a range of therapeutic modalities. Since its inception in 2013 and through a network of over 120 collaborators globally, RGC has developed one of the largest and richest human genetics datasets in the world by sequencing more than 2 million exomes.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company founded in 1999 that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
You are now leaving Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.
New York State Parks and the Department of Environmental Conservation, in partnership with the Office for People with Developmental Disabilities (OPWDD) and the NYS Division of Veterans' Services, will host free events to celebrate New York's spectacular outdoor spaces in this inclusive one-day event. Get Outdoors & Get Together Day brings people of all abilities, ages, identities, and backgrounds together for fun, healthful activities as part of the Governor' initiative to broaden the diversity of users and ensure inclusivity of access to state public lands.
Adaptive equipment will be available for select activities across participating sites. Please direct questions to individual participating sites for equipment availability and programs offered. All other accessibility-related inquiries should be directed to access...@parks.ny.gov.
Over the past years, systemd gained a number of components forbuilding Linux-based operating systems. While these componentsindividually have been adopted by many distributions and products forspecific purposes, we did not publicly communicate a broader visionof how they should all fit together in the long run. In this blog story Ihope to provide that from my personal perspective, i.e. explain how Ipersonally would build an OS and where I personally think OSdevelopment with Linux should go.
I figure this is going to be a longer blog story, but I hope itwill be equally enlightening. Please understand though that everythingI write about OS design here is my personal opinion, and not one of myemployer.
For the last 12 years or so I have been working on Linux OSdevelopment, mostly around systemd. In all those years I had a lotof time thinking about the Linux platform, and specificallytraditional Linux distributions and their strengths and weaknesses. Ihave seen many attempts to reinvent Linux distributions in one way oranother, to varying success. After all this most would probablyagree that the traditional RPM or dpkg/apt-based distributions stilldefine the Linux platform more than others (for 25+ years now), eventhough some Linux-based OSes (Android, ChromeOS) probably outnumberthe installations overall.
And over all those 12 years I kept wondering, how would I actuallybuild an OS for a system or for an appliance, and what are thecomponents necessary to achieve that. And most importantly, how can wemake these components generic enough so that they are useful ingeneric/traditional distributions too, and in other use cases than myown.
Before figuring out how I would build an OS it's probably good tofigure out what type of OS I actually want to build, what purpose Iintend to cover. I think a desktop OS is probably the mostinteresting. Why is that? Well, first of all, I use one of these for myjob every single day, so I care immediately, it's my primary tool ofwork. But more importantly: I think building a desktop OS is one ofthe most complex overall OS projects you can work on, simply becausedesktops are so much more versatile and variable than servers orembedded devices. If one figures out the desktop case, I think there'sa lot more to learn from, and reuse in the server or embedded case,then going the other way. After all, there's a reason why so much of thewidely accepted Linux userspace stack comes from people with a desktopbackground (including systemd, BTW).
7fc3f7cf58